![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1510695
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀå : Áö¿ªº° ºÐ¼® - ¼ö¼úÀ¯Çüº°, À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº° ¿¹Ãø(-2030³â)Asia Pacific Heart Transplant Market Forecast to 2030 - Regional Analysis - by Surgery Type, Type, and End User |
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀåÀº 2022³â 34¾ï 2,568¸¸ ´Þ·¯¿¡¼ 2030³â¿¡´Â 77¾ï 3,974¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿¹Ãø±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)Àº 10.7%·Î ÃßÁ¤µË´Ï´Ù.
³ëÀÎ Àα¸ Áõ°¡°¡ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀåÀ» ¹Ð¾î ¿Ã¸³´Ï´Ù.
³ëÀÎ Àα¸´Â CVD, Á¤Çü¿Ü°ú Áúȯ, ´ë»ç Áúȯ, ½Å°æ Áúȯ µî¿¡ °É¸®±â ½±½À´Ï´Ù. WHO¿¡ µû¸£¸é ¼¼°è °í·ÉÈ Àα¸´Â 2019³â 10¾ï¸í¿¡¼ 2050³â 21¾ï¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. Áß±¹°ú Àεµ´Â °¢°¢ 10¾ï ¸í ÀÌ»óÀ» Â÷ÁöÇÏ°í ¾Æ½Ã¾Æ Àα¸´Â 2020³â ½ÃÁ¡¿¡¼ 45¾ï ¸íÀ» µ¹ÆÄÇÏ¸ç ¼¼°è ÃÑ Àα¸ÀÇ Àý¹Ý ÀÌ»óÀ» Â÷ÁöÇÕ´Ï´Ù. ¾Æ½Ã¾ÆÀÎÀº 4¾ï 1,400¸¸¸íÀÌ µÉ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ÀÌ´Â 65¼¼ ÀÌ»óÀÇ ¹Ì±¹ÀÎ 3¾ï 3,140¸¸¸íÀ» ¾à 20% ¿ôµ¹°Ô µË´Ï´Ù. 2050³â¿¡´Â ¾Æ½Ã¾Æ ³ëÀÎ Àα¸´Â 9¾ï 2,300¸¸ ¸íÀ» ³ÑÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. µû¶ó¼ ³ëÀÎ Àα¸ Áõ°¡¿Í ½ÉºÎÀü À¯º´·ü Áõ°¡´Â ½ÉÀå ÀÌ½Ä ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀå °³¿ä
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀåÀº Áß±¹, Àεµ, ÀϺ», Çѱ¹, È£ÁÖ ¹× ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇÀ¸·Î ±¸ºÐµË´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå¿¡¼ °¡Àå ºü¸¥ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ª ½ÃÀå ¼ºÀåÀº Àå±â Á¦°øÀÇ Á߿伺¿¡ ´ëÇÑ °Ç° °ü¸® ÀÇ½Ä Áõ°¡¿Í Àå±â Á¦°ø¿¡ ´ëÇÑ ±àÁ¤ÀûÀΠŵµ¸¦ ÃËÁøÇÏ´Â ¼Ò¼È ¹Ìµð¾î ¸¶ÄÉÆÃÀÇ ±ÞÁõÀ¸·Î ÀÎÇÑ °ÍÀÔ´Ï´Ù. ¶ÇÇÑ, ÀÇ·á ÀÎÇÁ¶óÀÇ ¹ßÀü°ú »ý»ê ´É·ÂÀ» ³ôÀ̱â À§ÇÑ ÅõÀÚ Áõ°¡´Â ¿¹Ãø ±â°£ µ¿¾È ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. BioMed Central¿¡ °ÔÀçµÈ ±â»ç¿¡ µû¸£¸é Áß±¹¿¡¼´Â »ç¸Á ¿øÀÎÀÇ 40% ÀÌ»óÀÌ CVD¿¡ ±âÀÎÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ 2019³â¿¡´Â Áß±¹¿¡¼ ¾à 1¾ï 2,033¸¸ ¸íÀÌ CVD·Î °íÅë¹Þ°í ÀÖ½À´Ï´Ù. ±Þ¼ÓÇÑ »çȸ°æÁ¦ÀÇ ¹ßÀüÀº Áß±¹ÀεéÀÇ ¶óÀÌÇÁ½ºÅ¸ÀÏ¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, ±× °á°ú ½ÉºÎÀüÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Â ½ÉÀå°ú Ç÷°ü »óÅÂÀÎ CVD¿¡ °É¸± °¡´É¼ºÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÇöÀç, ½ÉÀå À̽ÄÀº ÁøÇàµÈ ½ÉºÎÀü¿¡ ´ëÇÑ À¯ÀÏÇÑ È¿°úÀûÀÎ Ä¡·á¹ýÀ¸·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. ±×·¯³ª ½ÉÀå ±âÁõÀÚÀÇ ¼ö°¡ Á¦ÇѵǾî Àֱ⠶§¹®¿¡ Áß±¹¿¡¼´Â ¿¬°£ ºÒ°ú 300¸í ¹Û¿¡ ½ÉÀå À̽ÄÀÌ ¾ø½À´Ï´Ù. µû¶ó¼ ½ÉºÎÀüÀ¸·Î °íÅë¹Þ´Â »ç¶÷µéÀº ½ÉÀå À̽ÄÀÇ ´ë±â ¸ñ·ÏÀÌ ±æ±â ¶§¹®¿¡ Àΰø ½ÉÀå À̽ÄÀ» ¼±ÅÃÇÕ´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÉÀåÀ̽ĽÃÀå ¼öÀͰú ¿¹Ãø(-2030³â)
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀåÀÇ ¼¼ºÐÈ
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀåÀº ¼ö¼ú À¯Çü, À¯Çü, ÃÖÁ¾ »ç¿ëÀÚ ¹× ±¹°¡º°·Î ±¸ºÐµË´Ï´Ù.
¼ö¼ú À¯Çü¿¡ µû¶ó ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀåÀº µ¿¼Ò¼º ½ÉÀå À̽İú À̼Ҽº ½ÉÀå À̽ÄÀ¸·Î À̺е˴ϴÙ. 2022³â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀå¿¡¼´Â µ¿¼Ò¼º ½ÉÀå ÀÌ½Ä ºÐ¾ß°¡ Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
À¯Çüº°·Î ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀåÀº ±âÁõÀÚ ¶óÀÌºê ½ÉÀå°ú Àΰø ½ÉÀåÀ¸·Î À̺е˴ϴÙ. 2022³â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀå¿¡¼´Â ±âÁõÀÚ ¶óÀÌºê ½ÉÀå ºÐ¾ß°¡ Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àΰø ½ÉÀå ºÎ¹®Àº ½É½Ç º¸Á¶ ÀåÄ¡¿Í Àüü Àΰø ½ÉÀåÀ¸·Î ºÐ·ùµË´Ï´Ù.
ÃÖÁ¾ »ç¿ëÀÚ¸¦ ±â¹ÝÀ¸·Î ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀåÀº º´¿ø, ½ÉÀå ¼¾ÅÍ µîÀ¸·Î ±¸ºÐµË´Ï´Ù. 2022³â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀå¿¡¼ º´¿ø ºÎ¹®Àº °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÕ´Ï´Ù.
±¹°¡º°·Î ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀåÀº Áß±¹, Àεµ, Çѱ¹, ÀϺ», È£ÁÖ ¹× ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇÀ¸·Î ±¸ºÐµË´Ï´Ù. Áß±¹Àº 2022³â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù.
Terumo Corp, Abbott Laboratories, SynCardia Systems LLC, BiVACOR Inc, BioVentrix Inc, LivaNova Plc´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀå¿¡¼ »ç¾÷À» Àü°³Çϰí ÀÖ´Â ¼±µµ ±â¾÷ÀÔ´Ï´Ù.
¸ñÂ÷
The Asia Pacific heart transplant market is expected to grow from US$ 3,425.68 million in 2022 to US$ 7,739.74 million by 2030. It is estimated to grow at a CAGR of 10.7% from 2022 to 2030.
Growing Geriatric Population Boosts Asia Pacific Heart Transplant Market
The geriatric population is prone to CVDs, orthopedic disorders, metabolic disorders, and neurological disorders, among others. According to the WHO, the aging population across the world is likely to rise from ~1 billion in 2019 to ~2.1 billion by 2050. With China and India accounting for more than one billion people each, Asia's population surpassed 4.5 billion as of 2020, making up more than half of the world's total population. Asians were predicted to number 414 million, which is around 20% more than the 331.4 million Americans who are 65 years of age or older. By 2050, it is expected that Asia will have over 923 million elderly population. Hence, the growing elderly population, along with the increasing prevalence of heart failure, fuels the heart transplant market growth.
Asia Pacific Heart Transplant Market Overview
The Asia Pacific heart transplant market is segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. Asia Pacific is expected to register the fastest CAGR in the global market during the forecast period. The market growth in this region is ascribed to the rise in healthcare awareness of the importance of organ donation and a surge in social media marketing to encourage a positive attitude toward organ donation. Additionally, advancing healthcare infrastructure and increasing investments to boost manufacturing capacities are projected to drive the Asia Pacific heart transplant market during the forecast period. According to an article published in BioMed Central, more than 40% of the deaths in China are attributed to CVDs. In addition, in 2019, about 120.33 million people suffered from CVDs in China. Rapid socioeconomic progress is impacting the lifestyle of the population in China, which, in turn, increases the chances of contracting CVDs, conditions of heart or blood vessels that may result in heart failure. At present, heart transplantation is the only well-known effective treatment for advanced heart failure. However, owing to the limited number of heart donors, only ~300 heart transplants are performed in China annually. Therefore, people suffering from heart failure opt for artificial heart transplants due to the long waiting list for heart transplantation.
Asia Pacific Heart Transplant Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Heart Transplant Market Segmentation
The Asia Pacific heart transplant market is segmented into surgery type, type, end user, and country.
Based on surgery type, the Asia Pacific heart transplant market is bifurcated into orthotopic heart transplantation and heterotopic heart transplantation. The orthotopic heart transplantation segment held a larger share of the Asia Pacific heart transplant market in 2022.
In terms of type, the Asia Pacific heart transplant market is bifurcated into donor live heart and artificial heart. The donor live heart segment held a larger share of the Asia Pacific heart transplant market in 2022. Further, artificial heart segment is categorized into ventricular assisted device and total artificial heart.
Based on end user, the Asia Pacific heart transplant market is segmented into hospitals, cardiac centres, and others. The hospitals segment held the largest share of the Asia Pacific heart transplant market in 2022.
Based on country, the Asia Pacific heart transplant market is segmented into China, India, South Korea, Japan, Australia, and the Rest of Asia Pacific. China dominated the Asia Pacific heart transplant market in 2022.
Terumo Corp, Abbott Laboratories, SynCardia Systems LLC, BiVACOR Inc, BioVentrix Inc, and LivaNova Plc are some of the leading companies operating in the Asia Pacific heart transplant market.
Table of Content